ICCG Publications

1. P Schein, RC Coombes, C Chilvers for the International Adjuvant trial in Gastric Cancer. A Controlled trial of FAM chemotherapy as adjuvant treatment for resected gastric carcinoma. Proc ASCO 1986 P 79 no 308

2. J Wils, RC Coombes, C Chilvers, A Palmer, J Bliss, D Amadori, G Beretta H Cortes-Funes, C McArdle, H Rauschecker, A Villar-Grimalt, P Schein for the ICCG. Randomised trial of FAM chemotherapy versus control as adjuvant treatment for resected gastric cancer. Proc ASCO 1988 P97 no 370

3. RC Coombes, PS Schein, CED Chilvers, J Wils, G Beretta, JM Bliss, A Rutten, D Amadori, H Cortes- Funes, A Villar-Grimalt, C McArdle, HF Rauscheker, E Boven, P Vassilopoulos, K Welvaart, E PintoFerreira, J Wig, C Gisselbrecht, P Rougier, E Woods for the ICCG.  A randomised trial comparing adjuvant fluoroucil, doxorubicin, and mitomycin with No treatment in operable gastric cancer. J Clin Oncol (1990) 8: 1362-1369

4. J Wils, JM Bliss, RC Coombes, D Amadori, G Fountzilas, HO Klein, E Pinto-Ferreira, H Reis, P Vassilopoulos, E Woods for the International Collaborative Cancer Group. Phase I-II study of sequential high dose MTX and 5FU combined with Epirubicin (FEMTX) in advanced gastric cancer. Proc XV Congress of European Society for Medical Oncology, Copenhagen (1990) Abst P6:3

5. JM Bliss, J Wils, G, Blijham, M Marty, A Milla Santos, CED Chilvers, E Woods for the International Collaborative Cancer Group. Toxicity analysis of a randomised trial comparing tamoxifen versus tamoxifen plus epirubicin in postmenopausal patients with node positive breast cancer. Proc XV Congress of European Society for Medical Oncology, Copenhagen (1990) Abst P3:16

6. Coombes RC, Bliss JM, Marty M, Wils J, Amadori D, Beretta G, Milla A, Aapro MS, Villar-Grimalt A, McArdle C, Chilvers CED, Coombes G, Woods E for the International Collaborative Cancer Group (ICCG). A randomised trial comparing adjuvant FEC with CMF in premenopausal patients with node positive resectable breast cancer. Proc Am Soc Clin Oncol 10:37 (1991) Houston.

7. Marty M, Bliss JM, Coombes RC, Wils J, Amadori D, Beretta G, Milla A, Aapro MS, Villar-Grimalt A, McArdle C, Chilvers CED, Woods E for the International Collaborative Cancer Group (ICCG). First interim results of a randomised study comparing FEC with CMF in premenopausal patients with node positive resectable breast cancer. Proc Adjuvant Therapy of Primary Breast Cancer, 4th International Conference, St Gallen (1992) Abst 58p.

8. J Wils, Bliss J, Marty M, Aapro MS, Amadori D, Beretta G, McArdle C, Pérez-Lopez FR, Richards M, Vassilopoulos P, Villar-Grimalt A, Chilvers CED, Coombes G, Woods E, RC Coombes for the International Collaborative Cancer Group (ICCG). Second interim analyses of a randomised study comparing FEC with CMF in premenopausal patients with node positive resectable breast cancer. Proc XVIIth Congress of the European Society for Medical Oncology, Lyon (1992) Abst 915.

9. J Wils, RC Coombes, J Bliss, M Law, G Fountzilas, H Reis, P Vassilopolos, HO Klein, E Pinto-Ferreira, A Tres, D Amadori, A Abad, E Woods for the International Collaborative Cancer Group. Phase I-II study of sequential high dose MTX and 5FU combined with epirubicin (FEMTX) in advanced gastric cancer. Vth EORTC symposium on research, diagnosis and treatment of Gastrointestinal Cancer, (1993) Porto1

0. J Wils, RC Coombes, M Marty, J Bliss, E Woods. Design and rationale of a randomised comparison of CMF v FEC in node positive premenopausal women with operable breast cancer. A trial of the ICCG (1993). Drugs 45 (suppl. 2): 46-50, 1993

11. M Marty on behalf of the ICCG. Epirubicin and the risk of Leukaemia. (1993) Correspondence  J Clin Oncol. 77:7 pp 1430-1435.

12. RC Coombes, CED Chilvers, D Amadori, F Medi, G Fountzilas, H Rauscheker, P Vassilopoulos, E PintoFerreira, G Vannozzi, JM Bliss, E Woods, J Wils for the ICCG. Randomised trial of epirubicin versus Fluorouracil in advanced gastric Cancer. Ann of Oncol 5: 33-36, 1994

13. J Wils, Wagener DJTh, Coombes RC, Fountzilas G, Bliss JM, M Law, Monaghan H, E Woods, for the International Collaborative Cancer Group (ICCG). Phase III trial of fluorouracil, methotrexate and epirubicin (FEMTX) versus FEMTX plus cisplatin (FEMTX-P) in advanced gastric cancer. (Poster ESMO 1994) Annals of Oncology 5 (suppl 8) no 392, 1994.

14. Marty M, Bliss JM, Coombes RC, Wils J, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Woods E Coombes G for the International Collaborative Cancer Group (ICCG). Cyclophosphamide (C), Methotrexate (M), Fluorouracil (F), (CMF) vs F-Epirubicin (E)-C (FEC) chemotherapy in premenopausal women with node positive breast cancer : results of a randomised trial. Proc Thirtieth Annual Meeting ASCO Dallas (1994). Abst 50

15. J Wils, Wagener DJTh, Coombes RC, Fountzilas G, Bliss JM, M Law, Monaghan H, E Woods, for the International Collaborative Cancer Group (ICCG). Phase III trial of fluorouacil, methotrexate and epirubicin (FEMTX) versus FEMTX plus cisplatin (FEMTX-P) in advanced gastric cancer. (Poster) UICC XVI International Cancer Congress Nov 1994.

16. J Wils, RC Coombes, J Bliss, M Law, G Fountzilas, D Amadori, A Abad-Esteve, HO Klein, E Pinto-Ferreira, H Reis, P Vassilopolos, A Tres, E Woods, for the International Collaborative Cancer Group. Phase I-II study of sequential high dose MTX and 5FU combined with epirubicin (FEMTX) in advanced gastric cancer. GI Cancer, 1995, Vol 1 pp 55-59.

17. Wils J, Wagener DJTh, Coombes RC, Fountzilas G, Bliss JM, M Law, Monaghan H, E Woods, for the International Collaborative Cancer Group (ICCG). Phase III trial of fluorouracil, methotrexate and epirubicin (FEMTX) versus FEMTX plus cisplatin (FEMTX-P) in advanced gastric cancer. (Poster) 2nd International Conference on Biology, prevention & treatment of gastrointestinal malignancies. 1995.

18. Coombes RC, Bliss JM, Wils J, Morvan F, Espie M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Perez-Lopez FR, Vassilopoulos P, Pinto Ferreira E, Chilvers CED, Coombes G, Woods EM, Marty M, for the International Collaborative Cancer Group (ICCG). Adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy in premenopausal women with axillary node positive operable breast cancer: results of a randomised trial. J Clin Oncol 14, No 1, 1996. 35-45

19. Wils J, Bliss JM, Coombes RC, Woods E, Coombes G, Blijham GH, Erdkamp F, Flickers M, de Greve J, Hilten H , Morvan F,Espie M, Olmos T, Perez-Lopez FR, Vassilopoulos P, Wals J, Praga C, Marty M for the International Collaborative Cancer Group (ICCG). A Multicentre Randomised Trial of Tamoxifen vs Tamoxifen plus Epirubicin in Postmenopausal Women with Node Positive Breast Cancer. Proc Am Soc Clin Oncol 15:6 (1996).

20. JA Wils, JM Bliss*, M Marty, G Coombes, C Fontaine, F Morvan, T Olmos, FR Pérez-López, P Vassilopoulos, E Woods and RC Coombes. Epirubicin plus tamoxifen versus tamoxifen alone in node positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group (ICCG). Journal of Clinical Oncology, Vol 17, No 17 (July) 1999: pp1-11.

21. Wils J, Nitti D, Guimaraes-Dos Santos J, Fountzilas G, Conte F, Sava C, Tres A, Sanches E, Homewood J, Courveur ML, Hall E, Baron B, Lise M, ICCG and EORTC, London UK, EORTC, Brussels, Belgium, ICCG, London UK, ICCG Data Centre, London, UK, EORTC Data Center, Brussels, Belgium (2002) ‘Randomized phase lll studies of adjuvant chemotheraphy with FAMTX or FEMTX in resected gastric cancer.  Pooled results of studies from the EORTC Gl-group and the ICCG. Proceedings of ASCO Vol 21 p 131a.

22. Wils J, Nitti D, Guimaraes-Dos Santos J, Fountzilas G, Conte F, Sava C, Tres A, Sanches E, Homewood J, Courveur ML, Hall E, Baron B, Lise M, ICCG and EORTC, London UK, EORTC, Brussels, Belgium, ICCG, London UK, ICCG Data Centre, London, UK, EORTC Data Center, Brussels, Belgium (2002) ‘Randomized phase lll studies of adjuvant chemotheraphy with FAMTX or FEMTX in resected gastric cancer.  Pooled results of studies from the EORTC Gl-group and the ICCG. Proceedings of ASCO Vol 21 p 131a.

23. Coombes RC, Bliss JM, Gibson LJ, Hall E, Massimini G, on behalf of the IES Steering Committee; Imperial College Faculty of Medicine, Charing Cross Hospital, London, UK, Clinical Trials & Statistics Unit, Institute of Cancer Research, Sutton, UK, Pharmacia Corporation, Viale Pasteur 10, Nerviano (MI), Italy. (2002) ‘The Intergroup Exemestane Study (IES) – design and patient characteristics Proceedings of ASCO Vol 21 p 44b. 2002.

24. Gibson LJ, Bertelli G, Hall E, Bliss JM, Massimini G, Lionetto R, Coombes RC; IES Steering Committee; Medical Oncology, London, UK; Imperial College Faculty of Medicine, Charing Cross Hospital, S Croce General Hospital, Cuneo, Italy; Institute of Cancer Research, Sutton, UK; Pharmacia Corporation, Viale Pasteur 10, Nerviano (MI) Italy; National Institute for Cancer Research, Genova, Italy (2002) ‘Transvaginal ultrasound (TVUS) findings in patients participating in the Intergroup Exemestane Study (IES). Proceedings of ASCO Vol 21 p 48b. 2002

25. Bliss JM, Wils J, Marty M, Morvan F, Espie M, Coombes G, Lawrence D, Coombes RC on behalf of the International Collaborative Cancer Group (2002)  ‘Evaluation of the tolerability of FE50C versus FE75C in a prospective randomized trial in adjuvant breast cancer patients.’  Proceedings of ASCO Vol 21 p 51b. 2002.

26. Marty M, Hall E, Wils J, Morvan F, Espie M, Bliss JM, Coombes RC on behalf of the International Collaborative Cancer Group; ICCG Data Centre, London, UK. (2002) ‘Evaluation of tolerability of CMF versus FEC in a randomized trial in node negative poor risk primary breast cancer patients’. Proceedings of ASCO Vol 21 p 69a. 2002.

27. ML Murray, PS Hupperets, F Erdkamp, M Marty, JM Bliss, E Hall, MA Emson and RC Coombes on behalf of the International Collaborative Cancer Group, ICCG Data Centre, London, UK. (2002) A Multicentre Randomised Trial of Sequential Epirubicin and Docetaxel versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients. British Oncological Association Annual Scientific Meeting, 1-3 September 2002 Type of ref: Abstract

28. Fallowfield L J, Coster S, Murray R A, Coombes R C, Gibson L, Bliss J, Hall E. on behalf of the Intergroup Exemestane Study Steering Committee. University of Sussex, Brighton, UK; Imperial College School of Medicine, Charing Cross Hospital, London, UK; Institute of Cancer Research, Sutton, UK. Patient reported side effects after 2 to 3 years adjuvant tamoxifen,  25th San Antonio Breast Cancer Symposium Dec 11-14, 2002. Type of ref: Abstract

29. LJ Gibson, RC Coombes, JM Bliss, E Hall and G Massimini on behalf of the IES Steering Committee. ‘The Intergroup Exemestane Study (IES) - Design and Patient Characteristics.  British Oncological Association Annual Scientific Meeting, 1-3 September 2002. Type of ref: Abstract

30. Coombes RC, Bliss J, Hall E, Gibson L, Fallowfield L, Massimini G, and on behalf of the Intergroup Exemestane Study (IES). Under-reporting of symptoms in patients with early breast cancer (EBC) who have received tamoxifen treatment for 2 to 3 years. Proc ASCO 2003 . Ref Type: Abstract

31. Gibson L, Hall E, Bliss J, Carpentieri M, Massimini G, Coombes RC, and on behalf of the Intergroup Exemestane Study (IES). The Integroup Exemestane Study (IES): a model for collaboration. 3rd Joint meeting of International Society for Clinical Biostatistics and Society for Clinical Trials, London 20th-24th July, 2003 . 2003.  Ref Type: Abstract

32. Gibson LJ, Hall, E., Bliss JM, Emson MA, Carpentieri M, Massimini G, and Coombes RC. The Intergroup Exemestane Study (IES) - A model for collaboration. Controlled Clinical Trials 24, 222S. 2003. Ref Type: Abstract

33. Gibson LJ, Hall, E., Bliss JM, Emson MA, Carpentieri M, Massimini G, and Coombes RC. The Intergroup Exemestane Study (IES) - A model for collaboration. Joint NCRN / BODMA National Conference, Nottingham 8-9th September, 2003. Ref Type: Abstract

34.  R. Charles Coombes, David Vigushin, Edward Kanfer, Chris Gallagher, Anthony Howell, Robert Rubens, Maurice Slevin, Clare Peckitt, Marie Emson and Judith Bliss.
Randomised Trial of High Dose Therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes.
Proc ASCO 2003. Ref Type: Abstract

35. Marty M, Coombes RC, Peckitt C, Pérez López FR, Tres A, Morvan F, Tubiana-Mathieu N, Espié M, Bliss JM on behalf of the International Collaborative Cancer Group; ICCG Data Centre, London, UK. Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs. fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer.
Proc ASCO 2004.  Ref Type: Abstract 

36. Jones A, Emson MA, Hall E, Bliss JM, von Minckwitz G, Coombes RC. An International  Phase III Multicentre Double Blind Randomised Trial of Celecoxib versus Placebo in Primary Breast Cancer Patients. REACT -  Randomised EuropeAn Celecoxib Trial.  British Oncological Association (BOA 2004). Ref Type: Abstract.

37. Coombes et Al. A randomized trial of exemestane after 2-3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; Vol 350; 11 1081-1092 Ref Type: Original Article

38. Jacek Jassem, Emma Hall,  Judith M Bliss, Rekha Patel,  Claire F Snowdon, and R Charles Coombes,  on behalf of the Intergroup Exemestane Study (IES). Approaches to adjuvant chemotherapy in postmenopausal breast cancer patients in the Intergroup Exemestane Study.
Breast Cancer Research and Treatment 88 (Suppl 1) S63.2004: Ref Type: Abstract 1066

39. Gianfilippo Bertelli,  Emma Hall,  Judith M Bliss, Claire F Snowdon, and R Charles Coombes, on behalf of the Intergroup Exemestane Study (IES). Intergroup Exemestane Study: results of the endometrial sub-protocol.
Breast Cancer Research and Treatment 88 (Suppl 1) S35.2004: Ref Type: Abstract 402

40. R Charles Coombes,  Emma Hall,  Claire F Snowdon, and Judith M Bliss,  on behalf of the Intergroup Exemestane Study (IES). The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis.  Breast Cancer Research and Treatment 88 (Suppl 1) S7 2004. Ref Type: Abstract 3.

41. Robert E Coleman, Linda M Banks, Emma Hall, Deidre Price, Samia Girgis, Judith M Bliss and R Charles Coombes on behalf of the Intergroup Exemestane Study (IES). Intergroup Exemestane Study: 1 year results of the bone sub-protocol. Breast Cancer Research and Treatment 88 (Suppl 1) S35.2004: Ref Type: Abstract 401

42. Lesley J Fallowfield, Miranda H Price, Emma Hall, R Charles Coombes and Judith M Bliss on behalf of the Intergroup Exemestane Study (IES). Intergroup Exemestane Study: results of the Quality of Life sub-protocol. Breast Cancer Research and Treatment 88 (Suppl 1) S8.2004: Ref Type: Abstract 4.

43. Coombes RC et al. Safety of Exemestane in the Intergroup Exemestane Study. JCO 23 (13): 3171-a-3172. 2005. Ref Type: Correspondence

44.  Banks et al. Skeletal effect of exemestane in patients with breast cancer – results from the Intergroup Exemestane Study (IES). JMBR 20(Suppl 1), S327. 2005 . Ref Type: Abstract

45. Coleman et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) – 2 year bone mineral density (BMD) and bone biomarker data. Breast Cancer Research and Treatment 94 (Suppl 1), S233. 2005. Abstract No: 5076

46. Fallowfield L et al. Quality of Life in the Intergroup Exemestane Study: A randomized trial of Exemestane versus continued Tamoxifen after 2 to 3 years of Tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24: 910-917, 2006.

47. Jassem J, Coombes RC, Ireland B, Hall E, Snowdon CF, Bliss JM on behalf of the IES Group. Approaches to post-mastectomy radiotherapy (PMRT) in the Intergroup Exemestane Study (IES). Proc ESTRO 2006. Ref Type: Abstract.

48. Coombes RC, Paridaens R, Jassem J, Van de Velde CJ, Delozier T, Jones SE et al. First mature survival analysis of the Intergroup Exemestane Study: a randomised trial in disease-free, postmenopausal patients with early breast cancer randomised to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. J Clin Oncol 2006; 24 (Suppl 18S), Abstract LBA527

49. Bliss JM, Kilburn L, Ireland B, Snowdon CF, Coombes RC, for the Intergroup Exemestane Study (IES). Tamoxifen washout - the effect on safety in the Intergroup Exemestane Study (IES).  Proc SABCS 2006. Ref type: abstract.

50. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007 Feb;8(2):119-27.

51. Coombes RC, Kilburn LS, Snowdon CF, Parideans R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM, on behalf of the Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559–70